#United States #Indianapolis #Eli Lilly #Mounjaro #Foundayo

Eli Lilly's Strong Start in 2026: Financial Highlights

Eli Lilly and Company has begun the year 2026 on an exceptional note, as reflected in its financial results for the first quarter. The company reported a remarkable 56% increase in revenue, totaling $19.8 billion, compared to $12.7 billion in the same quarter last year. This surge was primarily driven by significant volume growth, albeit somewhat affected by a decline in realized prices for two of its flagship products, Mounjaro and Zepbound.

David A. Ricks, Lilly's chair and CEO, expressed confidence in the company's performance, stating, "2026 is off to a strong start, we delivered 56% revenue growth in the first quarter and raised our full-year revenue guidance by $2 billion." This escalation in guidance indicates that Lilly anticipates annual revenue to fall between $82 billion and $85 billion, a substantial increase from previous forecasts.

Earnings Performance

The earnings per share (EPS) also witnessed a staggering growth rate, climbing by 170% on a reported basis to reach $8.26, while non-GAAP EPS escalated by 156% to $8.55. Notably, the reported EPS figures include $0.52 of acquired in-process research and development (IPRD) charges, down significantly from $1.72 in Q1 2025.

Product and Market Performance

The first-quarter financial results highlighted Lilly's successful product line, particularly observing impressive sales from Mounjaro, which recorded $8.7 billion in revenue, marking a 125% increase. This increase was largely due to heightened demand, despite a reduced realized price, as explained in their financial analysis. Zepbound also demonstrated significant growth, with Q1 sales rising 79% to $4.1 billion.

In terms of market geographies, sales in the U.S. reflected a 43% increase to $12.1 billion, primarily driven by strong volume from Mounjaro and Zepbound. Conversely, international sales outpaced U.S. performance, surging by 81% to $7.7 billion, underscoring the high demand for Lilly's offerings outside the U.S. The success of Mounjaro's addition to the National Reimbursed Drug List (NRDL) in China also contributed significantly to this growth.

Regulatory and Pipeline Developments

In addition to this robust financial performance, Lilly achieved key regulatory milestones, such as U.S. FDA approval for Foundayo (orforglipron), the first GLP-1 oral medication designed for weight loss that can be consumed without food or water restrictions. This approval marks a significant advancement in therapeutic options available for managing obesity and excess weight-related health issues.

Several pivotal pipeline successes were also reported, including promising Phase 3 results from Foundayo in treating adults with type 2 diabetes and obesity, as well as other notable developments across several therapeutic areas such as Immunology, Oncology, and Neuroscience.

Business Growth Initiatives

In tandem with these accomplishments, Lilly has been proactive in expanding its portfolio through strategic acquisitions. Recent agreements to acquire Orna Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics, and Ajax Therapeutics signify its commitment to drive innovation and enhance treatment options across various medical conditions.

Looking ahead, Lilly is set to hold a planned Investment Community Meeting on December 7, 2026, signaling ongoing transparency and engagement with investors as they navigate their growth trajectory.

In summary, Eli Lilly's outstanding Q1 performance not only demonstrates exceptional growth across all fronts but also accentuates the company's commitment to innovation and delivering impactful treatments to patients worldwide. Through its ongoing investments and broadening product pipeline, Lilly is position well for future success amidst the evolving pharmaceutical landscape.